Odanacatib developed by Merck & Co. is the only small molecular CTSK inhibitor candidate which demonstrated high therapeutic efficacy to increase bone mineral density in patients with osteoporosis (McClung et al., 2019; Stone et al., 2019). Here, CTSK is linked to osteoporosis.